# Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

> **NCT02354352** · PHASE3 · COMPLETED · sponsor: **Ohio State University** · enrollment: 52 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Eplerenone
- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT02354352
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-20
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-10-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354352, "Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02354352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*